JANUX THERAPEUTICS INC (JANX) competitors & alternatives
Health Care · NASDAQ
JANUX THERAPEUTICS INC (JANX)'s top competitors and alternatives — its most similar public companies — include Cue Biopharma, Inc. (CUE), CRISPR THERAPEUTICS AG (CRSP), Pyxis Oncology, Inc. (PYXS), ARTIVA BIOTHERAPEUTICS INC (ARTV), KYVERNA THERAPEUTICS INC (KYTX), CONTEXT THERAPEUTICS INC (CNTX), CANDEL THERAPEUTICS INC (CADL), NEKTAR THERAPEUTICS (NKTR), CABALETTA BIO INC (CABA), ARCUS BIOSCIENCES INC (RCUS), REPLIMUNE GROUP INC (REPL) and BICARA THERAPEUTICS INC (BCAX). These are JANUX THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top JANX competitors & alternatives
-
Cue Biopharma, Inc.CUEHealth Care
Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate…
$34.20 (as of 2026-07-22) · market cap $144M
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
Pyxis Oncology, Inc.PYXSHealth Care
Pyxis Oncology is a clinical-stage biopharma developing innovative antibody-drug conjugates (ADCs) that target the tumor microenvironment to improve efficacy…
$2.53 (as of 2026-07-22) · market cap $160M
-
ARTIVA BIOTHERAPEUTICS INCARTVHealth Care
Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials.
$10.02 (as of 2026-07-22) · market cap $487M
-
KYVERNA THERAPEUTICS INCKYTXHealth Care
Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful…
$7.40 (as of 2026-07-22) · market cap $452M
-
CONTEXT THERAPEUTICS INCCNTXHealth Care
Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer…
$0.61 (as of 2026-07-22) · market cap $56M
-
CANDEL THERAPEUTICS INCCADLHealth Care
Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic…
$10.09 (as of 2026-07-22) · market cap $739M
-
NEKTAR THERAPEUTICSNKTRHealth Care
A clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune diseases and cancer.
$69.32 (as of 2026-07-22) · market cap $2.4B
-
CABALETTA BIO INCCABAHealth Care
Cabaletta Bio is a clinical-stage biotechnology firm developing one-time, curative CAR T cell therapies aimed at resetting the immune system for patients with…
$2.75 (as of 2026-07-22) · market cap $449M
-
ARCUS BIOSCIENCES INCRCUSHealth Care
A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in…
$29.97 (as of 2026-07-22) · market cap $3.7B
-
REPLIMUNE GROUP INCREPLHealth Care
Replimune is developing engineered oncolytic viruses that directly kill tumors while triggering systemic anti-tumor immunity, with its lead candidate RP1 in…
$10.75 (as of 2026-07-22) · market cap $918M
-
BICARA THERAPEUTICS INCBCAXHealth Care
Bicara Therapeutics is developing a pipeline of bifunctional antibodies that precisely target and neutralize both EGFR and TGF-β pathways to improve treatment…
$27.96 (as of 2026-07-22) · market cap $1.9B
Not quite? Describe exactly what you want →
Peers are JANUX THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: JANUX THERAPEUTICS INC (JANX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.